The World Health Organization (WHO) has issued a medical product alert regarding falsified semaglutides, which are used to treat type 2 diabetes and obesity in some countries.

The alert highlights three falsified batches of the semaglutide brand Ozempic, detected in Brazil in October 2023, the United Kingdom in October 2023, and the United States in December 2023. The WHO Global Surveillance and Monitoring System (GSMS) has reported an increase in falsified semaglutide products in all regions since 2022. This alert is the first official notice from WHO following the confirmation of some of these reports.

“WHO advises healthcare professionals, regulatory authorities, and the public to be aware of these falsified batches of medicines,” said Dr. Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products. “We call on stakeholders to stop any usage of suspicious medicines and report them to relevant authorities.”

Shortage of supplies and increased falsification

The semaglutides, including the specific brand product that has been falsified, are prescribed to people with type 2 diabetes in order to lower their blood sugar levels. Semaglutides also reduce the risk of cardiovascular events. Most semaglutide products must be injected under the skin on a weekly basis but they are also available as tablets taken by mouth daily. These medicines are shown to suppress appetite in addition to lowering blood sugar levels, and therefore are being increasingly prescribed for weight loss in some countries.

WHO has been observing increased demand for these medicines as well as reports on falsification. These falsified products could have harmful effects to people’s health; if the products don’t have the necessary raw components, falsified medicines can lead to health complications resulting from unmanaged blood glucose levels or weight. In other cases, another undeclared active ingredient may be contained in the injection device, e.g. insulin, leading to an unpredictable range of health risks or complications.

Semaglutides are not part of WHO-recommended treatments for diabetes management due to their current high cost. The cost barrier makes these products unsuitable for a public health approach, which aims to ensure the widest possible access to medicines at the population level and to strike a balance between the best-established standard of care and what is feasible on a large scale in resource-limited settings. Also, there are more affordable treatments available for diabetes, with similar effects to those of semaglutides on blood sugar and cardiovascular risk.

WHO is currently working on a rapid advice guideline on possible use of GLP-1 RAs, including semaglutides, for treatment of obesity in adults and as part of a more comprehensive model of care. The term GLP-1 RAs stands for glucagon-like peptide-1 receptor agonists, which include semaglutides, for a class of medicines used for diabetes treatment to lower blood sugar and support weight loss.

Individual action

To protect themselves from falsified medicines and their harmful effects, patients who are using these products can take actions such as buying medicines with prescriptions from licensed physicians and avoid buying medicines from unfamiliar or unverified sources, such as those that may be found online.

People should always check packaging and expiry dates of medicines when they buy them, and use the products as prescribed. In the case of injectable semaglutides, patients should ensure they are stored in the refrigerator.

Kimera Abdul is a Senior Journalist with Plus News Uganda. He identifies as an adaptable and enthusiastic individual who works to inspire generations. He posses a Diploma and Broadcast journalism and has...

Leave a comment

Your email address will not be published. Required fields are marked *